Who makes Anti-Tlymphocyte Globulins?

Anti-Tlymphocyte Globulins is developed by Tianjin First Central Hospital.

What development phase is Anti-Tlymphocyte Globulins in?

Anti-Tlymphocyte Globulins is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Anti-Tlymphocyte Globulins

Tianjin First Central Hospital · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Anti-Tlymphocyte Globulins
Also known as	Grafalon, ATG-F
Sponsor	Tianjin First Central Hospital
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Observational Study to Evaluate the Safety and Efficacy of Polyclonal Antibodies in Simultaneous Pancreas Kidney Transplant Recipients (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Anti-Tlymphocyte Globulins CI brief — competitive landscape report
Anti-Tlymphocyte Globulins updates RSS · CI watch RSS
Tianjin First Central Hospital portfolio CI